Whole-body FDG-PET imaging in the management of patients with cancer.
about
Positron emission tomography agent 2-deoxy-2-[18F]fluoro-D-glucose has a therapeutic potential in breast cancerImaging in breast cancer: Single-photon computed tomography and positron-emission tomographyCase report: PET/CT, a cautionary talePrognostic value of SUVmax measured by Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography with Computed Tomography in Patients with Pancreatic Cancer.Prognostic Value of Volume-Based Metabolic Parameters Measured by (18)F-FDG PET/CT of Pancreatic Neuroendocrine Tumors.Development and validation of queries using structured query language (SQL) to determine the utilization of comparison imaging in radiology reports stored on PACS.Meta-analysis of the diagnostic performance of [18F]FDG-PET and PET/CT in renal cell carcinoma.Detection of lymph node involvement in hematologic malignancies using micromagnetic resonance lymphangiography with a gadolinum-labeled dendrimer nanoparticleAssessment of α-fetoprotein targeted HSV1-tk expression in hepatocellular carcinoma with in vivo imaging.Prognostic Value of SUVmax Measured by Pretreatment Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Patients with Ewing Sarcoma.Relation Between F-18 FDG Uptake of PET/CT and BRAFV600E Mutation in Papillary Thyroid Cancer.Generalized whole-body Patlak parametric imaging for enhanced quantification in clinical PETThe use of positron emission tomography with (18)F-fluorodeoxyglucose for the diagnosis of vascular graft infection.FDG PET imaging of childhood sarcomas.Pharmacokinetics, metabolism, biodistribution, radiation dosimetry, and toxicology of (18)F-fluoroacetate ((18)F-FACE) in non-human primatesUnexpected FDG-PET uptake in the gastrointestinal tract: endoscopic and histopathological correlations.Possible role of F18-FDG-PET/CT in the diagnosis of endocarditis: preliminary evidence from a review of the literature.F18-FDG-PET/CT for evaluation of intraductal papillary mucinous neoplasms (IPMN): a review of the literature.Biological markers of hepatocellular carcinoma for use as selection criteria in liver transplantation.18-F fluorodeoxyglucose uptake in positron emission tomography as a pathological grade predictor for renal clear cell carcinomas.Significance of preoperative fluorodeoxyglucose-positron emission tomography in prediction of tumor recurrence after liver transplantation for hepatocellular carcinoma patients: a Japanese multicenter study.Whole-body direct 4D parametric PET imaging employing nested generalized Patlak expectation-maximization reconstruction.Experimental study on the therapeutic effect and underlining mechanisms of positron in pancreatic cancer cellsDynamic whole-body PET parametric imaging: II. Task-oriented statistical estimation.Dynamic whole-body PET parametric imaging: I. Concept, acquisition protocol optimization and clinical application.Prognostic value of (18)F-fluorodeoxyglucose positron emission tomography in patients with extrahepatic bile duct cancer.Role of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in predicting the pathologic response to preoperative chemoradiation therapy in patients with resectable T3 pancreatic cancer.High SUV uptake on FDG-PET/CT predicts for an aggressive B-cell lymphoma in a prospective study of primary FDG-PET/CT staging in lymphoma.FDG-PET imaging to detect and characterize infectious disorders; an unavoidable path for the foreseeable future.F-18 FDG uptake on positron emission tomography as a predictor for lymphovascular invasion in patients with lung adenocarcinoma.Physiological ¹⁸F-FDG uptake by the spinal cord: is it a point of consideration for cancer patients?Role of FDG-PET/CT in detecting lymphomatous bone marrow involvement in patients with newly diagnosed diffuse large B-cell lymphoma.PET/CT incidental detection of second tumor in patients investigated for pancreatic neoplasms.
P2860
Q24802651-E29DF6F9-1A6A-4539-A468-33E85FADE7A5Q24810786-1DF426BE-B118-42E3-ADC4-601FB17AD10DQ33293417-F29339E0-E51D-47CF-930D-8FA77A9BBCE5Q33704543-94527C85-5E13-43F4-A6E9-0602363C818EQ34090931-83EA8FE2-96A9-4DC6-B853-541830E9C405Q34599522-82A7E19C-1894-4151-85B1-161E34D974FFQ34644707-CBE8FF2C-2F05-48F3-B49F-278EE968C734Q34769916-2F7C629B-F990-4959-9A48-B6620048DED7Q35068110-19A1386E-08A3-4F70-AB3F-B13A68F8BC6BQ35995816-7A083883-FBCE-4416-B049-5229380363D7Q36359047-1DD6C5D0-2A64-4FB9-9FDB-D241F3CC1F01Q36454757-6DCA5799-0CEB-4051-86FA-776464ABFB1DQ37028750-A8E3ACEB-2D37-44ED-B989-BBDB6BB70152Q37480204-D5676D79-2E92-470C-BD5C-CE054F1FC4CDQ37518179-EBF39FE9-AD19-40E5-896E-55C421654924Q37708042-222FD5E4-0722-425A-ACE6-825E01CA762DQ37960822-8652A0AC-D1A7-4674-A447-6838BC4D6C6DQ38073684-748C6A69-5172-49D1-BCBE-62CEE08B0828Q38269467-A18A56D1-D74C-4DFC-9007-76001274FF10Q38411777-4EE8A14B-0732-4472-BBAE-E8036C0A1DB9Q39223475-93DD1E7F-AB01-4A97-82A8-B6A7E7DF617CQ39627244-07ACEBD4-B650-4FA9-94CD-EC3C64F19ADEQ41612946-42E221BA-4123-405D-B838-D7FF2E79458DQ41878745-77A8F13C-7C67-4CA2-8553-25D5E306A9E9Q41983073-739B7580-A1A5-4011-AEB2-4172254C4DE4Q44017699-C6182871-2960-45A6-ACF1-F284580C7AB0Q44116708-146F0927-B626-416F-823C-9D1835CF24DFQ45993978-03B5E4D3-CBAF-4CDB-A437-7017A6D351E1Q48065050-79301ABC-CF8F-46D1-80FA-8E22F680C7E1Q52991183-D5F767C1-9174-4E4A-AD6B-40296E00B4ECQ53180282-74F9FF3A-0479-42CB-8295-54E5FCBDEFAEQ53196142-B675E455-5B1A-48E6-8705-13C529FD1DB1Q55279829-F2DC0D78-7808-42FA-A45A-509CA2FE4664
P2860
Whole-body FDG-PET imaging in the management of patients with cancer.
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Whole-body FDG-PET imaging in the management of patients with cancer.
@ast
Whole-body FDG-PET imaging in the management of patients with cancer.
@en
Whole-body FDG-PET imaging in the management of patients with cancer.
@nl
type
label
Whole-body FDG-PET imaging in the management of patients with cancer.
@ast
Whole-body FDG-PET imaging in the management of patients with cancer.
@en
Whole-body FDG-PET imaging in the management of patients with cancer.
@nl
prefLabel
Whole-body FDG-PET imaging in the management of patients with cancer.
@ast
Whole-body FDG-PET imaging in the management of patients with cancer.
@en
Whole-body FDG-PET imaging in the management of patients with cancer.
@nl
P356
P1476
Whole-body FDG-PET imaging in the management of patients with cancer
@en
P2093
Abass Alavi
Roland Hustinx
P356
10.1053/SNUC.2002.29272
P577
2002-01-01T00:00:00Z